Literature DB >> 26910609

The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition.

Tomohiko Aihara1, Tatsuya Toyama2, Masato Takahashi3, Yutaka Yamamoto4, Fumikata Hara5, Hiromitsu Akabane6, Tomomi Fujisawa7, Takashi Ishikawa8, Shigenori Nagai9, Rikiya Nakamura10, Junji Tsurutani11, Yoshinori Ito12, Hirofumi Mukai13.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26910609     DOI： 10.1007/s12282-016-0670-y

Source DB:  PubMed          Journal:  Breast Cancer        ISSN： 1340-6868            Impact factor:   4.239


× No keyword cloud information.
  15 in total

1.  Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.

Authors:  Verin Lertjanyakun; Nathorn Chaiyakunapruk; Susumu Kunisawa; Yuichi Imanaka
Journal:  Pharmacoeconomics       Date:  2018-09       Impact factor: 4.981

2.  The Impact of Treatment Preferences in Second-Line Chemotherapy on the Prognosis of HER2-Negative Metastatic Breast Cancer.

Authors:  Hirofumi Mukai; Yasuhiro Hagiwara; Kentaro Imi; Hirotsugu Isaka; Kenichi Watanabe; Yutaka Matsuyama
Journal:  Oncology       Date:  2017-08-24       Impact factor: 2.935

3.  A Case of Pure Mucinous Breast Carcinoma in a 25-Year-Old Female Who Showed Complete Pathological Response to Neoadjuvant Chemotherapy despite Poor Clinical Response.

Authors:  Pei Du; Chunjie Hou; Jinglan Tang; Ying Liu; Qiaohong Hu; Hongfeng He; Kefeng Lu; Lucou Chen
Journal:  Breast Care (Basel)       Date:  2019-12-12       Impact factor: 2.860

4.  Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial.

Authors:  Takeru Shiroiwa; Takashi Fukuda; Kojiro Shimozuma; Mitsuko Mouri; Yasuhiro Hagiwara; Takuya Kawahara; Shozo Ohsumi; Yasuo Hozumi; Yoshiaki Sagara; Yasuo Ohashi; Hirofumi Mukai
Journal:  BMC Cancer       Date:  2017-11-17       Impact factor: 4.430

5.  APOBEC3B gene expression as a novel predictive factor for pathological complete response to neoadjuvant chemotherapy in breast cancer.

Authors:  Yoshitaka Fujiki; Yutaka Yamamoto; Aiko Sueta; Mutsuko Yamamoto-Ibusuki; Lisa Goto-Yamaguchi; Mai Tomiguchi; Takashi Takeshita; Hirotaka Iwase
Journal:  Oncotarget       Date:  2018-07-17

6.  Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2-Positive Breast Cancer and Other Solid Tumors.

Authors:  Ophelia Yin; Yuan Xiong; Seiko Endo; Kazutaka Yoshihara; Tushar Garimella; Malaz AbuTarif; Russ Wada; Frank LaCreta
Journal:  Clin Pharmacol Ther       Date:  2020-12-06       Impact factor: 6.875

7.  Pathological complete response of HER2-positive breast cancer to trastuzumab and chemotherapy can be predicted by HSD17B4 methylation.

Authors:  Satoshi Fujii; Satoshi Yamashita; Takeshi Yamaguchi; Masato Takahashi; Yasuo Hozumi; Toshikazu Ushijima; Hirofumi Mukai
Journal:  Oncotarget       Date:  2017-03-21

8.  Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study.

Authors:  Norikazu Masuda; Reiki Nishimura; Masato Takahashi; Kenichi Inoue; Shinji Ohno; Hiroji Iwata; Yuko Mori; Satoshi Hashigaki; Yasuaki Muramatsu; Takashi Nagasawa; Yoshiko Umeyama; Masakazu Toi
Journal:  Cancer Sci       Date:  2018-02-22       Impact factor: 6.716

9.  Avoidance and Period-Shortening of Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer in Stages I and II: Importance of Ki-67 Labeling Index and the Recognition of Apocrine-Type Lesions.

Authors:  Koichi Kubouchi; Kyosuke Shimada; Takamichi Yokoe; Yutaka Tsutsumi
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

10.  Radiogenomics of magnetic resonance imaging and a new multi-gene classifier for predicting recurrence prognosis in estrogen receptor-positive breast cancer: A preliminary study.

Authors:  Yukiko Tokuda; Masahiro Yanagawa; Kaori Minamitani; Yasuto Naoi; Shinzaburo Noguchi; Noriyuki Tomiyama
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.